Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company”), a life sciences company developing precision genetic medicines for ...

Kyle Bryant was diagnosed with Friedreich's Ataxia, or FA, at 17 years old. Friedreich's Ataxia is a a rare neuromuscular disease that affects 1 in 50,000 people. Over the last ...

Solid Biosciences Inc.’s SLDB share price has dipped by 14.97%, which has investors questioning if this is right time to buy.

Biomed Industries, Inc- logo NA-831 for Alzheimer's Disease NA-931 for weight loss Biomed Industries, Inc. CEO to Chair Neuro ...

Leerink lowered the firm’s price target on Lexeo Therapeutics (LXEO) to $18 from $19 and keeps an Outperform rating on the shares. The firm ...

Citi says a share overhang has been removed after Larimar Therapeutics (LRMR) announced it has received FDA alignment on an accelerated ...

Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver ...

Larimar Therapeutics, Inc. (Nasdaq: LRMR) has announced significant progress in its nomlabofusp program for Friedreich’s ...

Biogen enhances its portfolio and margins amidst market challenges and competition. Click here to find out why BIIB stock is ...

Anthony Monaco was a very active teen—involved in soccer, wrestling, and even cross country—but he always felt a little awkward physically. It started with running a little differently than the kids ...

After getting a green light from the European Commission, Biogen’s Skyclarys is the first approved medicine for the inherited neurological disease Friedreich’s ataxia (FA) in the EU.

Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study - - Preclinical muri ...